Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro

International Journal of COPD

Volumn 3, Issue 4, 2008, Pages 781-790

  Asano, Kazuhito ^a   Shikama, Yusuke ^a   Shibuya, Yasuhiro ^a   Nakajima, Hiroaki ^a   Kanai, Ken Ichi ^b   Yamada, Naohiro ^b   Suzaki, Harumi ^b  

^a SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

In vitro; Lung fibroblasts; Matrix metalloproteinases; Suppression; Tiotropium

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; TIOTROPIUM BROMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG FIBROBLAST; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; BRONCHODILATOR AGENTS; CELLS, CULTURED; CHOLINERGIC ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; FIBROBLASTS; HUMANS; LUNG; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NF-KAPPA B; RNA, MESSENGER; SCOPOLAMINE DERIVATIVES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 60249094602     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Babusyte A, Stravinskaite K, Jeroch J, et al. 2007. Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD. Respir Res, 8:81-9.
2. Baraldo S, Bazzan E, Zanin ME, et al. 2007. Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest, 132:1733-40.
3. Barchowsky A, Frleta D, Vincenti MP. 2000. Intergration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathway at the collagenase-1 promotor: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine, 12:1469-79.
4. Casaburi R, Mahler DA, Jones PW, et al. 2002. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 19:205-6.
5. Cataldo D, Munaut C, Noel A, et al. 2000. MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol, 123:259-67.
6. Demedts IK, Brusselle GG, Bracke KR, et al. 2005. Matrix metalloproteinases in asthma and COPD. Current Opinion Pharmacol, 5:257-63.
7. De Clark YA, Darville MI, Eeckhout Y, et al. 1994. Characterization of the promotor of the gene encoding human tissue inhibitor of metalloproteinase-2 (TIMP-2). Gene, 139:185-91.
8. Domaij H, Yucel-Lindberg T, Modeer T. 2002. Signal pathways involved in the production of MMP-1 and MMP-3 in human gingival fibroblasts. Eur J Oral Sci, 110:302-6.
9. Disse B. 2001. Antimuscarinic treatment for lung diseases from research to clinical practice. Life Sci, 68:2557-64.
10. Dusser D, Bravo ML, Iacono P. 2006. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J, 27:547-55.
11. Elkington PTG, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax, 61:259-66.
12. Gosens R, Bos IS, Zaagsma J, et al. 2005. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med, 171:1096-102.
13. Hamid Q, Cosio M, Lim S. 2004. Inflammation and remodeling in chronic obstructive pulmonary diseases. J Allergy Clin Immunol, 114:1479-81.
14. Herouy Y, Mellos P, Bandemir E, et al. 2001. Inflammation in stasis dermatitis upregulates MMP-1, MMP-2, and MMP-13 expression. J Dermatol Sci, 25:198-205.
15. Hogg JC, Chu F, Utokaparch S, et al. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med, 350:2645-53.
16. Hoshino M, Nakamura Y, Sim JJ, et al. 1998. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol, 102:783-8.
17. Hunter I, Nixon GF. 2006. Spatial compartmentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways in human airway smooth muscle cells: lipid rafts are essential for TNF-α-mediated activation of RhoA but dispensable for the activation of the NF-κB and MAPK pathways. J Biol Chem, 281:34705-15.
18. Ikeda K, Kobayashi S, Suzuki M, et al. 2002. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol, 366:97-103.
19. Imai K, Dalal SS, Chen ES, et al. 2001. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med, 163:786-91.
20. Jeffery PK. 2004. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc, 1:176-83.
21. Kang MJ, Oh YM, Lee JC, et al. 2003. Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow. J Korean Med Sci, 18:821-7.
22. Keam SJ, Keating GM. 2004. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med, 3:247-68.
23. Lagente V, Manoury B, Nenan S, et al. 2005. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Bras J Med Biol Re, 38:1521-30.
24. Lazaar AL, Amrani Y, Hsu J, et al. 1998. CD40-mediated signal transduction in human airway amooth muscle. J Immunol, 161:3120-7.
25. Lowrey G, Henderson N, Blakey JD, et al. 2008. MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD. Respir Med, 102:845-51.
26. Martin MT, Hove-Madsen L, Jimenz M. 2004. Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon. Neurogastroenterol Motil, 16:175-83.
27. Meriane M, Duhamel S, Lejeune L, et al. 2006. Cooperation of matrix metalloproteinases with the RhoA/Rho kinase and mitogen-activated protein kinase: Kinase-1/extracellular signal-regulated kinase signaling pathways is required for the shingosine-1-phosphate-induced mobilization of marrow-derived stroma cells. Stem Cells, 24:2557-65.
28. Murphy G, Docherty AJ. 1992. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol, 7:120-5.
29. Mong PY, Petrulio C, Kaufman HL, et al. 2008. Activation of Rho Kinase by TNF-α is required for JNK activation in human pulmonary microvascular endothelial cells. J Immunol, 180:550-8.
30. Nagase H. 1997. Activation mechanisms of matrix metalloproteinase. Biol Chem, 378:151-60.
31. Nee L, Tuite N, Ryan MP, et al. 2007. TNF-alpha and IL-1 beta-mediated regulation of MMP-9 and TIMP-1 in human glomelular mesangial cells. Nephron Exp Nephrol, 107:73-86.
32. Ohnishi K, Takagi M, Kurokawa Y, et al. 1998. Matrix-metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest, 78:1077-87.
33. Ohtake A, Ukai M, Hatanaka T, et al. 2004. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol, 492:243-50.
34. Okamoto SI, Mukaida N, Yasumoto K, et al. 1994. The interleukin-8, AP-1 and kB-like sites are genetic end targets of FK-506-sensitive pathway accompanied by calcium mobilization. J Biol Chem, 269:8582-9.
35. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. 2007. Effect of tiotropium on sputum and serum inflammatory markers and exacerbation in COPD. Eur Res J, 30:472-8.
36. Profita M, Bonanno A, Siena L, et al. 2008. Acetylcholine mediates the release of IL-9 in human bronchial epithelial cells by a NFκB/ ERK-dependent mechanism. Eur J Pahrmacol, 582:145-53.
37. Rodrigo GJ, Nannini LJ. 2007. Tiotropium for the treatment of stable chronic obstructive pulmonary diseases: a systemic review with meta-analysis. Pulm Pharmacol Ther, 20:495-502.
38. Sato H, Seiki M. 1993. Regulation of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene, 8:395-405.
39. Sato T, Koike L, Miyata Y, et al. 2002. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by a polymethoxy flavonoid, results in augmentation of tissue inhibitor of mettaloproteinase-2 production and suppression of production of matrix metalloproteinases-2 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res, 62:1025-9.
40. Segura-Valdez L, Pardo A, Gaxiola M, et al. 2000. Upregulation of elatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest, 117:684-94.
41. Suzaki H, Asano K, Yu M, et al. 2003. Influence of roxithromycin on inflammatory cytokine production from nasal polyp fibroblasts in vitro. Acta Otolaryngol, 123:637-42.
42. Turner NA, O'Regan DJ, Ball SO, et al. 2005. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the Rho/ROCK pathway and reducing MMP-9 mRNA levels. FASB J, 19:804-6.
43. Vincken W, Van Noord JA, Greefhorst AP, et al. 2002. Improved health outcomes in patients with COPD during lyr's treatment with tiotropium. Eur Respir J, 19:217-24.
44. Ventura JJ, Kennedy NJ, Lamb JA, et al. 2003. c-Jun NH2-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Med. Cell Biol, 23:2871-82.
45. Wasylyk C, Gutman A, Nicholson R, et al. 1991. The c-Ets oncoprotein activates the stromelysin prompter through the same elements as several non-nuclear oncoprotein. EMBO J, 10:1127-34.